ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 14.3% from a year ago
Cash & equivalents stood at $56.4M at the end of Q1 FY2026, up 14.3% from a year earlier and up 23.5% from the prior quarter. Over 3 fiscal years it compounded at -11.9% a year.
Context
- Cash & equivalents amounted to 12.9% of total assets at the end of Q1 FY2026, down 7.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +14.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 45.67M USD
- Year-over-year change
- -23.1%
- 4-year CAGR
- -33.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.67M | -23.1% |
| FY2024 | 2024-12-31 | 59.41M | +154.0% |
| FY2023 | 2023-12-31 | 23.38M | -65.0% |
| FY2022 | 2022-12-31 | 66.84M | -70.4% |
| FY2021 | 2021-12-31 | 226.01M | — |
Cash & Equivalents vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's Mar 2026 cash & equivalents of $56.4M is the 8th highest of the 11 companies compared; the peer median is $75.74M.
- Its year-over-year change of +14.3% is the 5th highest of 11, against a peer median of -5.4%.
- Cash & equivalents amounts to 12.9% of total assets for ORIC, versus a peer median of 24.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $258.6M | +4.3% | +17.5% | 34.7% | |
| Mar 2026 | $165.55M | +40.8% | +39.9% | 72.7% | |
| Sep 2026 | $151.67M | +49.1% | +9.4% | 16.9% | |
| Mar 2026 | $130.89M | -15.0% | +22.0% | 27.7% | |
| Mar 2026 | $84.96M | -15.7% | -32.5% | 20.6% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $62.1M | +24.5% | -34.7% | 17.8% | |
| Mar 2026 | $56.4M | +14.3% | -11.9% | 12.9% | |
| Mar 2026 | $51.83M | -29.7% | +0.6% | 5.0% | |
| Mar 2026 | $40.1M | +702.2% | -29.7% | 15.8% | |
| Mar 2026 | $25.13M | -15.9% | +16.5% | 98.9% | |
| Peer median (excluding ORIC) | $75.74M | -5.4% | +5.0% | 24.2% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 226.01M | 66.84M | 23.38M | 59.41M | 45.67M |
| Short-term Investments | 10.97M | 139.43M | 184.8M | 196.55M | 235.82M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.19M | 4.41M | 6.29M | 6.98M |
| Total Current Assets | 240.52M | 210.46M | 212.6M | 262.25M | 288.47M |
| Property, Plant & Equipment (Net) | 2.41M | 14.25M | 12.01M | 2.92M | 9.07M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 43.39M | 22.42M | 27.34M | 0 | 111.25M |
| Tax Assets | 0 | 3.18M | 2.68M | 0 | 2.11M |
| Other Non-current Assets | 12.32M | 49K | 61K | 8.97M | 98K |
| Total Non-current Assets | 58.12M | 39.9M | 42.09M | 11.89M | 122.54M |
| Total Assets | 298.64M | 250.36M | 254.69M | 274.14M | 411M |
| Account Payables | 1.89M | 1.32M | 944K | 1.55M | 3.82M |
| Short-term Debt | 0 | 2.66M | 2.75M | 0 | 3.33M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.8M | 6.09M | 10.23M | 7.65M | 13.26M |
| Total Current Liabilities | 15.15M | 15.39M | 20.46M | 24.85M | 20.42M |
| Long-term Debt | 0 | 0 | 0 | 0 | 4.11M |
| Deferred Tax Liabilities | 0 | 3.18M | 2.68M | 0 | 2.11M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 10.52M | 0 | 0 | 6.17M | (4.11M) |
| Total Non-current Liabilities | 10.52M | 12.62M | 10.14M | 6.17M | 6.22M |
| Total Liabilities | 25.67M | 28.01M | 30.6M | 31.02M | 26.64M |
| Common Stock | 4K | 5K | 6K | 7K | 11K |
| Retained Earnings | (245.11M) | (334.23M) | (434.93M) | (562.77M) | (692.24M) |
| Accumulated OCI | (103K) | (1.29M) | 258K | 379K | 786K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 272.98M | 222.35M | 224.09M | 243.12M | 384.36M |
| Total Debt | 1.93M | 12.1M | 10.21M | 3.18M | 11.55M |
| Net Debt | (224.08M) | (54.74M) | (13.17M) | (56.22M) | (34.12M) |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.